TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05612945

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity interval training group (HIIT)
Description: Exercise training sessions will consist in an alternation of brief periods (≤ 60 s) of work performed at high intensity and brief period of passive rest.~Patient will be asked to complete 1 set of 10-15x60-s (or 2 sets of 5-7x60-s) walking intervals. The training intensity in the HIIT group will be set at ≥85% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-to-moderate intensity training group (LowMod group)
Description: Exercise training sessions will consist in an alternation of periods of work performed at moderate exercise intensity and period of passive rest. The training approach of the LowMod group will be similar to the training prescription usually adopted in patients with claudication. The exercise training intensity will be set at ≤76% HRpeak recorded during the maximal cardiopulmonary exercise test.~The training intervention will consist of 36 walking sessions spread over 12 weeks. Each training session will lasted 30-60 min. The training intervention will be performed on a treadmill (Cosmed T150, Itlay), which is equipped with harness and chest belt to secure the patients and prevents falling. Each session started with a 5-min walking warm-up and ended with a 5min cool-down. During all the exercise training sessions, HR of the subjects will be continuously monitored (Polar M430, Finland).
Study: NCT06511778

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemoblast Bellows application
Description: Hemoblast bellows is a hemostatic agent clinically proven effective on the validated SPOT GRADE scale for minimal, mild, and moderate bleeding. Patients will have the Hemoblast bellows applied during on pump sternotomy surgery.
Study: NCT05790876

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SSO2 therapy
Description: SSO2 therapy consists of overoxygenating the patient's blood and delivering it to the origin of the LAD for 60 min. Improvement in CMD will be assessed by comparing angio-IMR before and after 60 minutes of SSO2 therapy measured on conventional angiographic images
Study: NCT05616442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketotifen
Description: Mast cell stabilizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Dietary supplement
Study: NCT05577741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisensory virtual reality pod (SENSIKS©)
Description: Six sessions of 20 minutes of mindfulness.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive bike (Vélo-cognitif®)
Description: Six sessions of 20 minutes of cognitive bike (pedal + cognitive games).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Standard of care treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Standard of care treatment
Study: NCT06407011

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The CON group did not have any intervention but usual care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swedish massage prior circuit breathing training group (SBT)
Description: Participants Swedish massage prior circuit breathing training 3 days/week, 12 weeks. They perform Swedish massage using techniques such as stroking, kneading, and tapping the upper muscle area of the body for 20 minutes per day. Then, they do circuit breathing exercises for about 30 minutes per day, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit breathing training group (CBT)
Description: Participants perform circuit breathing exercises for about 30 minutes per day, 3 days/week, 12 weeks, comprising 3 sets of 4 breathing exercises (triflow, power breath, windmill, and balloon blowing), with 1-minute rest between each exercise and 2 minutes between each set.
Study: NCT05923723

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIBNUTRITION
Description: The dietary product selected for the study is commercially known as FIBNUTRITION, marketed in Colombia by Bio-Nutrition S.A.S with sanitary registration number NSA-001942-2016.~Ingredients of the product:~Flaxseed, Chia seeds, Psyllium, Polydextrose, Oat flour, Apple, Orange, Artificial flavor (Orange), Pineapple, Nopal, Xanthan gum (thickener), Silicon dioxide, Stevia (Natural sweetener), Lactobacillus Acidophilus Bifidus Casei (Prebiotics), Sodium Benzoate (Preservative), and Turmeric (Natural colorant).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a dietary product composed of maltodextrin, cornstarch, orange flavoring, and stevia.
Study: NCT05828108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bitopertin
Description: Dose Escalation: Monthly (every 4 weeks) up to a maximum dose of 60 mg bitopertin (5 mg, 10mg, 20mg, 40mg, 60mg). At each monthly (4 week) interval, a complete blood count (CBC) with differential and a reticulocyte analysis (including reticulocyte hemoglobin) will be collected prior to taking the higher dose. If the absolute reticulocyte count (ARC) is 60,000 /microL or higher, the subject will hold at the current dose level (or return to that level if escalation has already occurred) for an additional 4 weeks. If, after 8 weeks at that dose, response criteria are met this will be considered the minimum effective dose (MED) and shall be the treatment dose throughout the remainder of the study unless modifications are indicated.
Study: NCT04883463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural stimulation
Description: Epidural electrical stimulation implant weekly sessions for 21 months.
Study: NCT05821257

Intervention type: OTHER
Intervention: Evaluation of the arm swing during gait
Description: Evaluation of the arm swing during gait: The difference between the maximum flexion and extension of the shoulder is the arm swing amplitude during walking. The arm swing amplitude will be evaluated 2-dimensionally with the help of the Kinovea video player.

Intervention type: OTHER
Intervention: Evaluation of the arm swing during gait
Description: Evaluation of the arm swing during gait: The difference between the maximum flexion and extension of the shoulder is the arm swing amplitude during walking. The arm swing amplitude will be evaluated 2-dimensionally with the help of the Kinovea video player.

Intervention type: OTHER
Intervention: Functional Tests
Description: To understand the changes in functional mobility, Two Minute Walk Test (2MWT), Timed Up and Go (TUG) and Timed 25Foot Walk Test (T25FW) were conducted.
Study: NCT01321294

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic anti-reflux surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic anti-reflux surgery
Study: NCT05472831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAILAMOS dance program plus MIND diet
Description: The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute MIND diet session per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAILAMOS dance program plus Health Education
Description: The refined BAILAMOS program is a Latin dance, Spanish-language intervention that encompasses six dance styles (Merengue, Cha Cha Cha, Bachata, Salsa, Cumbia and Samba). The program meets twice weekly for 60 minutes per session during 6-months via Zoom. The experimental group will also receive one, 60 minute Health Education session per week.
Study: NCT06141018

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cross-linked intra-articular hyaluronic acid
Description: Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.
Study: NCT04870112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PD-L1 antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PD-L1 antibody
Study: NCT06141018

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in the treatment arm will receive 3 ml, 90 mg hyaluronic acid injection intra-articularly, while the ones in the placebo arm will receive 3 ml saline injection intra-articularly. The groups will be crossed-over at 3rd month.
Study: NCT04870112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study: NCT04619199

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood sample performed at the inclusion and during the follow-up.
Study: NCT06261918

Intervention type: PROCEDURE
Intervention: Influence of metabolic syndrome on the achievement of pathological complete response
Description: The proposed activity aims to assess the transcriptional and epimetabolic profile of locally advanced luminal or HER2+ or triple negative breast cancer in patients with/without metabolic syndrome to predict the therapeutic response to neoadjuvant chemotherapy.

Intervention type: PROCEDURE
Intervention: Influence of metabolic syndrome on the achievement of pathological complete response
Description: The proposed activity aims to assess the transcriptional and epimetabolic profile of locally advanced luminal or HER2+ or triple negative breast cancer in patients with/without metabolic syndrome to predict the therapeutic response to neoadjuvant chemotherapy.
Study: NCT04450173

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT04835480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OrsHSA
Description: OsrHSA a recombinant HSA, which was expressed and purified from the plant Oryza sativa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HSA
Description: Albutein® 20% (ALBUMIN HUMAN INFUSION 20% 50ML)
Study: NCT04734951

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Power/resistance exercise program
Description: participants will complete a power/resistance program during 14 weeks. The exercise program will consist of training to improve muscle strength, neuromotor skills, flexibility, endurance, and a greater emphasis on maximum strength and power. The intensity will be set according the estimated repetition to failure.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Power/resistance exercise program
Description: participants will complete a power/resistance program during 14 weeks. The exercise program will consist of training to improve muscle strength, neuromotor skills, flexibility, endurance, and a greater emphasis on maximum strength and power. The intensity will be set according the estimated repetition to failure.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HMB supplementation
Description: Daily oral supplementation with 237 ml of a polymeric nutritional formula added with 1.5 g of HMB (Ensure Advance®)
Study: NCT06097182

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Post-biotic (Colonic-Delivery capsule)
Description: 250mg post-biotic once daily in a polymer coated vegan gelatine capsule (colonic delivery)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Post-biotic (Regular Administration capsule)
Description: 250mg post-biotic once daily in a regular uncoated vegan gelatine capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule
Study: NCT06613269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NY104 PET/CT
Description: 68Ga-NY104 PET/CT will be performed at baseline, 6 months, 12 months, and 24 months after radiation therapy if the tumor is under control. If CT or MRI shows any suspicious recurrence or metastasis, 68Ga-NY104 PET/CT can be performed at the decision of the urology oncologist or radiation oncologist.~The scan begins 1 hour after intravenous injection of 68Ga-NY104.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Description: 18F-FDG PET/CT will be performed at baseline and 6 months after radiation therapy. The scan begins 1 hour after intravenous injection of 18F-FDG.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy will be delivered to cover as much metastasis as possible if not all. For new lesions after radiation plus systemic therapy, if the new lesions are considered suitable for RT, RT can be delivered again without changing systemic therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic therapy
Description: Systemic therapy will be delivered to patients to control the tumor. Possible regimen includes targeted therapy alone, immunotherapy alone, and targeted therapy combined with immunotherapy. The treatment regimen will be decided according to the urology oncologist.
Study: NCT06615947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic gait training
Description: RAGT group, will be trained 3-times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly. Training intensity will be monitored and standardized using the Borg Rating of Perceived Exertion scale, and will progress from 'fairly light' to 'somewhat hard'.~Progression will occur by increasing the number of steps in each session and decrease the level of assistance.~Participants will be secured with the appropriately sized harness and attached to an overhead body-weight support system. Each session will begin with a 3-5-minute warm-up in the continuous passive mode (cadence \~40-45 steps/minute). The participant will then be transitioned into the adaptive training phase for practicing repetitive floor walking for up to 30 minutes. During this phase, the force produced by the robot is modulated to support the effort of the patient in producing a typical walking pattern.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tRHB
Description: Participants randomize to receive a tRHB, will be trained 3 times per week, with an intensity of 40 to 60 minutes, and duration over 8-weeks. Progression will occur by increasing the session intensity weekly.~A standardized protocol based on the usual clinical practice of physiotherapy in people with multiple sclerosis will be follow, according to patient characteristics, to design the sessions based on the patient objectives to be achieved, choosing the type of specific exercises to be performed based on the patient's condition and with the possibility of adapting them to their evolution during the twenty-four sessions.
Study: NCT06097182

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 250mg Maltodextrin once daily in a regular uncoated vegan gelatine capsule
Study: NCT05825781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: i.v.
Study: NCT04870112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Chemotherapy
Study: NCT05202782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Given PO
Study: NCT05825781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perjeta®
Description: i.v.
Study: NCT05769062

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single digit pelvic exam
Description: The exam takes approximately 5 minutes and uses a single digit to palpate the pelvic floor muscles, during which patients will rate pain on a scale of 0-10 at 5 paired locations.
Study: NCT04537650

Intervention type: DIAGNOSTIC_TEST
Intervention: Videofluoroscopic Swallowing Study (VFSS)
Description: A standardized dynamic radiographic examination of oropharyngeal swallowing

Intervention type: DIAGNOSTIC_TEST
Intervention: Videofluoroscopic Swallowing Study (VFSS)
Description: A standardized dynamic radiographic examination of oropharyngeal swallowing
Study: NCT06548048

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement containing plant derived phenolics
Description: Dietary supplement containing plant derived phenolics

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystaline cellulose
Description: Microcrystaline cellulose (MCC)
Study: NCT04778566

Intervention type: DIAGNOSTIC_TEST
Intervention: Cologuard test
Description: Cologuard is a stool-DNA screening test for detecting colon cancer
Study: NCT05042505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10Mg Tab
Description: Dapa group (n = 50): Patients with diabetes mellitus will receive Dapagliflozin 10 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Sita group (n = 50): Patients with diabetes mellitus will receive sitagliptin 100 mg once daily
Study: NCT05947760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Magnesium Sulfate
Description: Participants will receive IV Magnesium Sulfate intraoperatively.
Study: NCT05294302

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eSCCIP/eSCCIP-SP
Description: eSCCIP/eSCCIP-SP is a psychosocial eHealth intervention for PCCC. It consists of four self-guided, web-based modules (including an introductory module) and three telehealth sessions with a study interventionist.
Study: NCT05768074

Intervention type: OTHER
Intervention: Qualitative Interview
Description: Therapists and agency leaders receiving intervention from the main study will participate in qualitative interviews
Study: NCT05294302

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Coping Space
Description: Coping Space is a psychosocial informational website for PCCC.
Study: NCT06230198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retrograde autologous priming (RAP)
Description: sites follow an institutional policy of routine use of retrograde autologous priming (RAP) during cardiac surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Crystalloid priming
Description: sites implement crystalloid priming use during cardiac surgery
Study: NCT05030428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inclisiran sodium 300 mg
Description: Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneously injected on Day 1, Month 3 (Day 90) and every 6 months thereafter until EOS visit
Study: NCT06154252

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CABA-201 following preconditioning with fludarabine and cyclophosphamide
Description: Single intravenous infusion of CABA-201 at a single dose level following preconditioning with fludarabine and cyclophosphamide
Study: NCT06429059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astaxanthin
Description: Astaxanthin is a red-orange natural pigment belonging to a group of carotenoids called xanthophylls. In nature, astaxanthin is synthesized by microalgae and phytoplankton and biomagnifies in higher marine animals through the food chain. Natural astaxanthin is available as capsules, soft gels, tablets, powders, biomass, creams, energy drinks, oils and extracts and often contains other carotenoids. The compound is available as a United States Pharmacopeia (USP) verified supplement which ensures federally recognized standards for quality and purity (https://www.quality-supplements.org/verified-products/verified-products-listings).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Protandim
Description: Protandim is an oral tablet derived from five different plants: Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), Curcuma longa (turmeric) and Bacopa monniera.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: Melatonin is a hormone that has long been known to play a role in regulating sleep. Melatonin supplements are commonly used to treat insomnia, but in recent years, melatonin has been found to play a wider role in human physiology including the potential regulation of autophagy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: The active ingredient in MitoQ is ubiquinone, the same as found in coenzyme Q10 and idebenone. However, the ubiquinone in MitoQ is attached to a positively charged, lipophilic molecule called TPP (triphenyl phosphonium), which allows it to selectively accumulate in mitochondria. This makes it more potent than untargeted ubiquinone analogs at protecting mitochondria in cultured cells. It can be administered orally and, at least in animals, can cross the blood brain barrier and accumulate in brain mitochondria.